Vitrafy Life Sciences (VFY) investor relations material

Technology and innovation

• Developed disruptive cryopreservation technology combining hardware and software, achieving over 100% improvement in sample quality compared to market standards.

• LifeChain software platform enables end-to-end sample tracking and quality assurance, supporting new industry standards.

• Next-generation freezing device and compliant software are market-ready, with medical device certification targeted for mid-2026 in North America.

• Technology extends shelf life of biological materials from days to years, reducing waste and enabling rapid processing.

• Robust IP portfolio with over 13 patents and 50 filings supports competitive advantage.

Commercialization and market strategy

• Focused on scaling in animal reproduction, blood platelets, and cell and gene therapy markets, prioritizing unregulated and high-volume sectors.

• Commercially ready to scale animal reproductive market globally; progressing in North America for blood platelets and cell/gene therapy.

• Managed service revenue model with recurring software and consumables revenue; targeting large blood collection networks for rapid proliferation.

• Forecasts small margin in year one, with software margins exceeding 80% recurring from year two onward.

• AUD 25 million cash and AUD 4.8 million government grant support scaling and market entry.

Partnerships, trials, and milestones

• Collaborating with U.S. Army Institute of Surgical Research; phase I blood platelet trial showed over 89% viability, far exceeding current standards.

• Phase II of U.S. blood platelet trial underway in San Antonio, with completion expected by end of Q3 and commercial agreement discussions to follow.

• Recent joint presentation at American Blood and Biotherapies Conference highlighted platelet wastage and Vitrafy's solution.

• Active conversations with both defense and civilian blood collection organizations, including Red Cross equivalents.

• Inbound interest growing in cell and gene therapy, with half the market accessible now and full clinical access expected post-certification in 2026.